Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Short Bowel Syndrome Treatment Protocol

Introduction to Teduglutide

  • Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves intestinal absorption and promotes weaning from parenteral nutrition (PN) in patients with short bowel syndrome (SBS), according to the American Gastroenterological Association 1
  • Teduglutide increases intestinal villus height and crypt depth, enhancing intestinal absorption, as stated by the European Society for Clinical Nutrition and Metabolism 2, 3
  • It increases wet weight absorption by approximately 750g/day, with a limited effect on energy absorption (<250 kcal/day), as reported by the European Society for Clinical Nutrition and Metabolism 2, 3

Treatment Protocol

Pre-Treatment Evaluation

  • A colonoscopy should be performed before starting treatment to confirm the absence of colorectal polyps or malignancies, as recommended by the American College of Gastroenterology 1, 4
  • Teduglutide is contraindicated in patients with active gastrointestinal malignancies, according to the National Comprehensive Cancer Network 1
  • Patients with a history of non-gastrointestinal malignancies (especially within 5 years) should avoid using teduglutide, as advised by the American Society of Clinical Oncology 1

Monitoring

  • Regular colonoscopies should be performed to monitor for polyps or malignancies, as recommended by the American College of Gastroenterology 1, 4
  • Parenteral nutrition should be adjusted and tapered in a planned manner, according to the American Society for Parenteral and Enteral Nutrition 1

Clinical Efficacy and Safety

  • Teduglutide may increase the risk of growing gastrointestinal polyps or malignancies due to its growth factor properties, as warned by the American Gastroenterological Association 1, 4
  • Long-term use of teduglutide requires continuous monitoring for tumor promotion risk, as stated by the European Society for Clinical Nutrition and Metabolism 2, 3

Treatment Positioning

  • Teduglutide should be used only in carefully selected patients after optimizing dietary therapy and conventional short bowel syndrome treatment, as recommended by the American Gastroenterological Association 1, 4
  • Teduglutide should be prescribed by experienced physicians and used in facilities where objective evaluation is possible, according to the European Society for Clinical Nutrition and Metabolism 4, 5
  • Patients should be fully informed about the benefits (possibility of parenteral nutrition weaning, improvement in quality of life) and risks (adverse effects, long-term safety concerns) of teduglutide treatment, as advised by the American College of Gastroenterology 1, 4

Safety Profile and Surveillance Recommendations for Teduglutide (GLP‑2 Analog)

Overall Tolerability and Malignancy Surveillance

  • Teduglutide is generally well tolerated, with adverse effects mainly confined to the gastrointestinal tract; however, patients require lifelong endoscopic surveillance for gastrointestinal malignancy because of a potential tumor‑promoting risk. 6

Comparison with Growth Hormone Therapy

  • Compared with growth‑hormone therapy, teduglutide’s adverse‑event profile is predominantly gastrointestinal and less systemic, making it the preferred intestinal growth factor for patients with short‑bowel syndrome. 6, 7